Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: November 2, 2006
Last updated: March 9, 2016
Last verified: March 2016
To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment

Condition Intervention Phase
Idiopathic Short Stature
Drug: Genotropin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Four Year Open Label Multi Center Randomized Two Arm Study Of Genotropin In Idiopathic Short Stature Patients: Comparing An Individualized, Target Driven Treatment Regimen To Standard Dosing Of Genotropin

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Absolute On-target Difference (AOTD) at 24 Months [ Time Frame: 2 years ]
    This was defined as an absolute difference between the 24-month height standard deviation score (SDS) and targeted 24-month height SDS (10th percentile (%), or -1.3 SDS). SDS indicates how similar the participant was to the reference population. These were calculated using 2000 Center for the Disease Control (CDC) growth reference tables (by age and gender).

Secondary Outcome Measures:
  • Variability of Height SDS at 24 Months [ Time Frame: 2 years ]
    The continuous endpoint of variability of height SDS at 24 months was defined as the SD of the 24 month height SDS.

  • Time Cost (Months Until >= -2 SDS) [ Time Frame: 2 years ]
    Time cost was defined as the number of months needed until height SDS was within the normal limit (ie, >= -2SDS).

  • Computed Cost of Height Gain at 48 Months [ Time Frame: 4 years ]
    The computed cost of height gain was defined as the amount of drug used relative to the observed height-gain, in terms of mg/cm, this was calculated at Month 48.

  • Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months [ Time Frame: 4 years ]
    The estimated cost of long-term height gain until FAH was calculated.

  • Change From Baseline in Height SDS at 48 Months. [ Time Frame: 4 years ]
    Change in height SDS was measured at 48 months.

Enrollment: 316
Study Start Date: December 2006
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard
Standard daily HGH treatment
Drug: Genotropin
Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Active Comparator: Formula-based
Formula-based dose regimen
Drug: Genotropin
Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.


Ages Eligible for Study:   3 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prepubertal children with bone ages between 3 and 10 years of age for males and 3 and 9 years of age for females
  • Naive to Growth Hormone treatment

Exclusion Criteria:

  • Abnormal karyotype. Small Gestational Age and Skeletal dysplasia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00396097

  Show 43 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00396097     History of Changes
Other Study ID Numbers: A6281280
Study First Received: November 2, 2006
Results First Received: August 30, 2013
Last Updated: March 9, 2016

Keywords provided by Pfizer:
human growth hormone

Additional relevant MeSH terms:
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Endocrine System Diseases processed this record on May 25, 2017